- Home
- CGEN vs NOTE Comparison
CGEN vs NOTE Comparison
Compare CGEN & NOTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- NOTE
- Stock Information
- Founded
- CGEN 1993
- NOTE 2013
- Country
- CGEN Israel
- NOTE United States
- Employees
- CGEN N/A
- NOTE N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- NOTE EDP Services
- Sector
- CGEN Health Care
- NOTE Technology
- Exchange
- CGEN Nasdaq
- NOTE Nasdaq
- Market Cap
- CGEN 117.8M
- NOTE 97.9M
- IPO Year
- CGEN 2000
- NOTE N/A
- Fundamental
- Price
- CGEN $1.47
- NOTE $0.60
- Analyst Decision
- CGEN Strong Buy
- NOTE Strong Buy
- Analyst Count
- CGEN 1
- NOTE 6
- Target Price
- CGEN $4.00
- NOTE $2.63
- AVG Volume (30 Days)
- CGEN 216.5K
- NOTE 1.4M
- Earning Date
- CGEN 05-19-2025
- NOTE 05-12-2025
- Dividend Yield
- CGEN N/A
- NOTE N/A
- EPS Growth
- CGEN N/A
- NOTE N/A
- EPS
- CGEN N/A
- NOTE N/A
- Revenue
- CGEN $27,589,000.00
- NOTE $115,665,000.00
- Revenue This Year
- CGEN $11.81
- NOTE N/A
- Revenue Next Year
- CGEN $28.37
- NOTE $41.32
- P/E Ratio
- CGEN N/A
- NOTE N/A
- Revenue Growth
- CGEN N/A
- NOTE N/A
- 52 Week Low
- CGEN $1.13
- NOTE $0.56
- 52 Week High
- CGEN $2.66
- NOTE $2.07
- Technical
- Relative Strength Index (RSI)
- CGEN 53.98
- NOTE 37.40
- Support Level
- CGEN $1.38
- NOTE $0.61
- Resistance Level
- CGEN $1.56
- NOTE $0.66
- Average True Range (ATR)
- CGEN 0.08
- NOTE 0.05
- MACD
- CGEN 0.02
- NOTE 0.00
- Stochastic Oscillator
- CGEN 68.97
- NOTE 9.33
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.